Biocryst Pharma Inc (BCRX)

$9.21 -0.18 (-1.92%)
Market Cap 1.94B
Revenue (ttm) 331.41M
Net Income (ttm) -226.54M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -68.36%
Debt to Equity Ratio -1.77
Volume 5,555,500
Avg Vol 2,549,444
Day's Range N/A - N/A
Shares Out 207.13M
Stochastic %K 70%
Beta 1.75
Analysts Strong Sell
Price Target $15.27

Latest News on BCRX

BioCryst to Present at Upcoming Investor Conferences

Feb 19, 2025, 7:00 AM EST - 3 days ago

BioCryst to Present at Upcoming Investor Conferences

BioCryst Launches ORLADEYO® (berotralstat) in Portugal

Feb 12, 2025, 7:00 AM EST - 10 days ago

BioCryst Launches ORLADEYO® (berotralstat) in Portugal

BioCryst to Present New ORLADEYO® (berotralstat) Results from APeX-P Pediatric Trial at 2025 American Academy of Allergy, Asthma & Immunology / World Allergy Organization Joint Congress

Feb 10, 2025, 8:30 AM EST - 12 days ago

BioCryst to Present New ORLADEYO® (berotralstat) Results from APeX-P Pediatric Trial at 2025 American Academy of Allergy, Asthma & Immunology / World Allergy Organization Joint Congress

BioCryst to Report Fourth Quarter 2024 Financial Results on February 24

Feb 10, 2025, 7:00 AM EST - 12 days ago

BioCryst to Report Fourth Quarter 2024 Financial Results on February 24

BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Feb 4, 2025, 7:00 AM EST - 18 days ago

BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

BioCryst Announces Preliminary Full Year 2024 ORLADEYO® (berotralstat) Net Revenue of $437 Million (+34 percent y-o-y)

Jan 10, 2025, 7:00 AM EST - 6 weeks ago

BioCryst Announces Preliminary Full Year 2024 ORLADEYO® (berotralstat) Net Revenue of $437 Million (+34 percent y-o-y)

BioCryst to Present at 43rd Annual J.P. Morgan Healthcare Conference

Jan 7, 2025, 7:00 AM EST - 6 weeks ago

BioCryst to Present at 43rd Annual J.P. Morgan Healthcare Conference

BioCryst Pharmaceuticals: Seasoned Blockbuster Makes It A Buy

Dec 9, 2024, 1:47 PM EST - 2 months ago

BioCryst Pharmaceuticals: Seasoned Blockbuster Makes It A Buy

BioCryst Launches ORLADEYO® (berotralstat) in Ireland

Nov 18, 2024, 2:00 AM EST - 3 months ago

BioCryst Launches ORLADEYO® (berotralstat) in Ireland

BioCryst Pharmaceuticals, Inc. (BCRX) Q3 2024 Earnings Call Transcript

Nov 4, 2024, 11:00 AM EST - 3 months ago

BioCryst Pharmaceuticals, Inc. (BCRX) Q3 2024 Earnings Call Transcript

BioCryst to Report Third Quarter 2024 Financial Results on November 4

Oct 21, 2024, 7:00 AM EDT - 4 months ago

BioCryst to Report Third Quarter 2024 Financial Results on November 4

BioCryst to Present New Real-World Evidence Showing Significant Reductions in Medical Visits and Hospitalizations After Starting ORLADEYO® (berotralstat)

Oct 14, 2024, 7:00 AM EDT - 4 months ago

BioCryst to Present New Real-World Evidence Showing Significant Reductions in Medical Visits and Hospitalizations After Starting ORLADEYO® (berotralstat)

BioCryst Begins Enrollment in Phase 1 Trial Evaluating BCX17725, a KLK5 Inhibitor, for the Treatment of Netherton Syndrome

Oct 2, 2024, 7:00 AM EDT - 5 months ago

BioCryst Begins Enrollment in Phase 1 Trial Evaluating BCX17725, a KLK5 Inhibitor, for the Treatment of Netherton Syndrome

U.S. Government Awards BioCryst $69 Million RAPIVAB® (peramivir injection) Contract for Strategic National Stockpile

Sep 30, 2024, 7:00 AM EDT - 5 months ago

U.S. Government Awards BioCryst $69 Million RAPIVAB® (peramivir injection) Contract for Strategic National Stockpile

BioCryst and the pan-Canadian Pharmaceutical Alliance (pCPA) Successfully Complete Negotiations for ORLADEYO® (berotralstat), an Oral, Once-daily Therapy for the Prevention of Hereditary Angioedema Attacks

Sep 17, 2024, 7:00 AM EDT - 5 months ago

BioCryst and the pan-Canadian Pharmaceutical Alliance (pCPA) Successfully Complete Negotiations for ORLADEYO® (berotralstat), an Oral, Once-daily Therapy for the Prevention of Hereditary Angioedema Attacks

BioCryst Presents New ORLADEYO® (berotralstat) Data at 7th Bradykinin Symposium

Sep 6, 2024, 2:00 AM EDT - 6 months ago

BioCryst Presents New ORLADEYO® (berotralstat) Data at 7th Bradykinin Symposium

BioCryst Pharmaceuticals, Inc. (BCRX) Q2 2024 Earnings Call Transcript

Aug 5, 2024, 11:44 AM EDT - 7 months ago

BioCryst Pharmaceuticals, Inc. (BCRX) Q2 2024 Earnings Call Transcript

BioCryst Reports Second Quarter 2024 Financial Results and Provides Business Update

Aug 5, 2024, 7:00 AM EDT - 7 months ago

BioCryst Reports Second Quarter 2024 Financial Results and Provides Business Update

BioCryst to Report Second Quarter 2024 Financial Results on August 5

Jul 22, 2024, 7:00 AM EDT - 7 months ago

BioCryst to Report Second Quarter 2024 Financial Results on August 5

Betting On BioCryst Pharmaceuticals: Orladeyo's Success Fuels Future Prospects

Jul 21, 2024, 7:30 AM EDT - 7 months ago

Betting On BioCryst Pharmaceuticals: Orladeyo's Success Fuels Future Prospects

ORLADEYO® (berotralstat) Approved in Peru

Jul 9, 2024, 7:00 AM EDT - 8 months ago

ORLADEYO® (berotralstat) Approved in Peru

BioCryst Presents New Real-world Evidence Showing Reductions in Attack Rates in HAE Patients with Normal C1-Inhibitor after Beginning ORLADEYO® (berotralstat) Treatment

Jun 2, 2024, 4:00 AM EDT - 9 months ago

BioCryst Presents New Real-world Evidence Showing Reductions in Attack Rates in HAE Patients with Normal C1-Inhibitor after Beginning ORLADEYO® (berotralstat) Treatment

BioCryst to Present New Data at 2024 Meeting of the European Academy of Allergy and Clinical Immunology

May 14, 2024, 7:00 AM EDT - 10 months ago

BioCryst to Present New Data at 2024 Meeting of the European Academy of Allergy and Clinical Immunology

ORLADEYO® (berotralstat) Approved in Mexico

May 13, 2024, 7:00 AM EDT - 10 months ago

ORLADEYO® (berotralstat) Approved in Mexico

BioCryst Presents New Real-world Evidence Showing Significant Reductions in Healthcare Resource Utilization Among Patients with HAE Following Initiation of ORLADEYO® (berotralstat)

May 9, 2024, 7:00 AM EDT - 10 months ago

BioCryst Presents New Real-world Evidence Showing Significant Reductions in Healthcare Resource Utilization Among Patients with HAE Following Initiation of ORLADEYO® (berotralstat)

BioCryst Pharmaceuticals, Inc. (BCRX) Q1 2024 Earnings Call Transcript

May 6, 2024, 11:42 AM EDT - 10 months ago

BioCryst Pharmaceuticals, Inc. (BCRX) Q1 2024 Earnings Call Transcript

BioCryst Reports First Quarter 2024 Financial Results and Provides Business Update

May 6, 2024, 7:00 AM EDT - 10 months ago

BioCryst Reports First Quarter 2024 Financial Results and Provides Business Update

BioCryst to Report First Quarter 2024 Financial Results on May 6

Apr 22, 2024, 7:00 AM EDT - 10 months ago

BioCryst to Report First Quarter 2024 Financial Results on May 6

BioCryst Announces Approval of ORLADEYO® (berotralstat) by the Brazilian Health Regulatory Agency

Apr 17, 2024, 4:30 AM EDT - 11 months ago

BioCryst Announces Approval of ORLADEYO® (berotralstat) by the Brazilian Health Regulatory Agency

BioCryst Pharmaceuticals, Inc. (BCRX) Q4 2023 Earnings Call Transcript

Feb 26, 2024, 11:29 AM EST - 1 year ago

BioCryst Pharmaceuticals, Inc. (BCRX) Q4 2023 Earnings Call Transcript

BioCryst Reports Fourth Quarter and Full Year 2023 Financial Results and Upcoming Key Milestones

Feb 26, 2024, 7:00 AM EST - 1 year ago

BioCryst Reports Fourth Quarter and Full Year 2023 Financial Results and Upcoming Key Milestones

BioCryst Presents New Real-world Data Showing Rapid, Substantial and Sustained HAE Attack Rate Reductions After Beginning ORLADEYO® (berotralstat) Treatment

Feb 23, 2024, 7:00 AM EST - 1 year ago

BioCryst Presents New Real-world Data Showing Rapid, Substantial and Sustained HAE Attack Rate Reductions After Beginning ORLADEYO® (berotralstat) Treatment

BioCryst Launches ORLADEYO® (berotralstat) in Italy

Feb 19, 2024, 7:54 AM EST - 1 year ago

BioCryst Launches ORLADEYO® (berotralstat) in Italy

BioCryst to Report Fourth Quarter 2023 Financial Results on February 26

Feb 12, 2024, 7:00 AM EST - 1 year ago

BioCryst to Report Fourth Quarter 2023 Financial Results on February 26

BioCryst to Present New ORLADEYO® (berotralstat) Real-world Data at 2024 American Academy of Allergy, Asthma & Immunology Annual Meeting

Feb 5, 2024, 7:00 AM EST - 1 year ago

BioCryst to Present New ORLADEYO® (berotralstat) Real-world Data at 2024 American Academy of Allergy, Asthma & Immunology Annual Meeting

BioCryst Announces Preliminary Full Year 2023 ORLADEYO® (berotralstat) Net Revenue of $325 Million, Provides 2024 Guidance and Accelerated Path to Profitability

Jan 5, 2024, 4:01 PM EST - 1 year ago

BioCryst Announces Preliminary Full Year 2023 ORLADEYO® (berotralstat) Net Revenue of $325 Million, Provides 2024 Guidance and Accelerated Path to Profitability

BioCryst to Present at 42nd Annual J.P. Morgan Healthcare Conference

Jan 3, 2024, 7:00 AM EST - 1 year ago

BioCryst to Present at 42nd Annual J.P. Morgan Healthcare Conference

BioCryst Announces Publication of Data from Open-label Extension of the APeX-2 Pivotal Trial of ORLADEYO® (berotralstat)

Dec 19, 2023, 7:00 AM EST - 1 year ago

BioCryst Announces Publication of Data from Open-label Extension of the APeX-2 Pivotal Trial of ORLADEYO® (berotralstat)

BioCryst: Factor D Inhibitor Data In 2024 Should Be Watched Closely

Dec 14, 2023, 6:34 PM EST - 1 year ago

BioCryst: Factor D Inhibitor Data In 2024 Should Be Watched Closely

BioCryst Announces Approval of ORLADEYO® (berotralstat) by the National Administration of Drugs, Foods, and Medical Devices (ANMAT) in Argentina

Nov 29, 2023, 7:00 AM EST - 1 year ago

BioCryst Announces Approval of ORLADEYO® (berotralstat) by the National Administration of Drugs, Foods, and Medical Devices (ANMAT) in Argentina

BioCryst Launches ORLADEYO® (berotralstat) in Spain

Nov 21, 2023, 7:00 AM EST - 1 year ago

BioCryst Launches ORLADEYO® (berotralstat) in Spain

BioCryst Presents New Real-world Data Showing Reduced Attack Rates in Patients with HAE with Normal C1-inhibitor Following Long-term Treatment with ORLADEYO® (berotralstat)

Nov 10, 2023, 7:00 AM EST - 1 year ago

BioCryst Presents New Real-world Data Showing Reduced Attack Rates in Patients with HAE with Normal C1-inhibitor Following Long-term Treatment with ORLADEYO® (berotralstat)

BioCryst R&D Day Highlights New Diversified Pipeline of First-in-Class/Best-in-Class Therapies with Five Programs Expected in Clinical Development in Next 24 Months

Nov 3, 2023, 12:03 PM EDT - 1 year ago

BioCryst R&D Day Highlights New Diversified Pipeline of First-in-Class/Best-in-Class Therapies with Five Programs Expected in Clinical Development in Next 24 Months

BioCryst and Clearside Biomedical Enter Partnership to Develop Avoralstat for Diabetic Macular Edema Using Clearside's Proprietary SCS Microinjector®

Nov 3, 2023, 12:00 PM EDT - 1 year ago

BioCryst and Clearside Biomedical Enter Partnership to Develop Avoralstat for Diabetic Macular Edema Using Clearside's Proprietary SCS Microinjector®

BioCryst Pharmaceuticals, Inc. (BCRX) Q3 2023 Earnings Call Transcript

Nov 2, 2023, 4:05 PM EDT - 1 year ago

BioCryst Pharmaceuticals, Inc. (BCRX) Q3 2023 Earnings Call Transcript

BioCryst Reports Third Quarter 2023 Financial Results and Provides Business Update

Nov 2, 2023, 7:00 AM EDT - 1 year ago

BioCryst Reports Third Quarter 2023 Financial Results and Provides Business Update

BioCryst to Present New ORLADEYO® (berotralstat) Data at Annual Scientific Meeting of American College of Allergy, Asthma & Immunology

Oct 27, 2023, 7:00 AM EDT - 1 year ago

BioCryst to Present New ORLADEYO® (berotralstat) Data at Annual Scientific Meeting of American College of Allergy, Asthma & Immunology

BioCryst Begins Enrollment in Proof-of-Concept Trial to Confirm Safe, Effective, Once-daily Dose of Oral Factor D Inhibitor, BCX10013

Oct 26, 2023, 7:00 AM EDT - 1 year ago

BioCryst Begins Enrollment in Proof-of-Concept Trial to Confirm Safe, Effective, Once-daily Dose of Oral Factor D Inhibitor, BCX10013

BioCryst to Host R&D Day on November 3

Oct 20, 2023, 7:00 AM EDT - 1 year ago

BioCryst to Host R&D Day on November 3

BioCryst to Report Third Quarter 2023 Financial Results on November 2

Oct 19, 2023, 7:00 AM EDT - 1 year ago

BioCryst to Report Third Quarter 2023 Financial Results on November 2